---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pharmacodynamics"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pharmacodynamics. Topics: Prevention of proteinuria in an interferon gamma-induced APOL1 G2 transgenic mouse model, Reversal of established proteinuria and eGFR decline with a close structural analog, Podocyte injury and proteinuria in APOL1 G1 transgenic mice: independent study, Preeclampsia phenotype in pregnant APOL1 G2/G2 transgenic mice, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Prevention of proteinuria in an interferon gamma-induced APOL1 G2 transgenic mouse model

> “In an APOL1 G2-homozygous transgenic mouse model, the injection of interferon gamma resulted in heavy proteinuria; in contrast, no proteinuria was seen when control Friend leukemia virus B (FVB) mice were exposed to interferon gamma.”
> “The prophylactic administration of inaxaplin (3 mg per kilogram three times daily) or vehicle for 3 days, with the first dose given on day 1 approximately 1.5 hours before the interferon gamma injection, significantly reduced the area under the curve for the mean urinary albumin-to-creatinine ratio in interferon gamma–injected G2-homozygous mice by an average of 74.1% (Figure 1D and Fig. S3).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

> “The potency of VX-147 was consistent across the in vitro functional assays described above (EC50 of approximately 2nM).”
> “Oral administration of VX-147 reduced proteinuria in IFNγ-induced APOL1 G2Hom mice by 74.1%.”

Source: [Zimmerman et al. (2021)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20213210s1419a~small-molecule-apol1-inhibitors-block-apol1-pore-function)

<a id="topic-2.1.2.6.2-2"></a>

### Reversal of established proteinuria and eGFR decline with a close structural analog

> “Compound 3 had a rapid effect at lowering the UACR (Fig. 4A and Supplementary Fig. 13).”
> “Analysis of the UACR AUC following compound intervention revealed a 97% reduction over the 8 days of compound administration (Fig. 4B).”
> “In transgenic APOL1 mouse models, we used Compound 3, a close analog of VX-147 with comparable potency and selectivity, to show that blockage of the APOL1 channel can both prevent and reverse APOL1-dependent proteinuria as well as preserve glomerular integrity.”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

> “Therapeutic intervention with Compound 3 at both intervention timepoints dramatically reduced proteinuria.”
> “Furthermore, therapeutic intervention with Compound 3 preserved the eGFR when administered early, and reversed eGFR decline back to near baseline level at a later timepoint of intervention.”

Source: [Blasio et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2024502b9s3w~small-molecule-apol1-channel-inhibitor-reduces-proteinuria)

<a id="topic-2.1.2.6.2-3"></a>

### Podocyte injury and proteinuria in APOL1 G1 transgenic mice: independent study

> “Within 48 hours, IFN-γ–treated mice developed significant proteinuria, which was almost completely attenuated with cotreatment with VX-147 (Figure 10, A and C).”
> “Importantly, these injury phenotypes were prevented by VX-147 treatment.”

Source: [Datta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/)

<a id="topic-2.1.2.6.2-4"></a>

### Preeclampsia phenotype in pregnant APOL1 G2/G2 transgenic mice

> “Furthermore, inaxaplin restored BP (93.49± 6.60 vs. 106.38± 5.50 mmHg; n=7-9; p<0.01) and fetal weight (1.051 ± 0.097 vs. 0.607 ± 0.169 g; n=10; p<0.01) and reduced albuminuria by 57.9±7.5% (n=5; p<0.01) in pregnant G2/G2 females.”

Source: [Rao et al. (2025)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2025kkecj205~inaxaplin-vx-147-mitigates-apol1-mediated-preeclampsia)

<a id="topic-2.1.2.6.2-5"></a>

### Projected inhibition of APOL1 ion flux at 15 mg and 45 mg once daily

> “Based on an exposure-response model, the exposures from the 15 mg dose are expected to result in approximately 90% inhibition in the in vitro ion flux model.”
> “Based on the exposure-response model referenced above, exposures from this dose are expected to result in over 96% inhibition in the in vitro ion flux model.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.6.2-6"></a>

### Onset and offset of proteinuria reduction in participants with APOL1-mediated FSGS

> “The treatment response from baseline was rapid and approximately linear, with a decrease seen by day 15; proteinuria continued to decrease through week 13 (Figure 2B).”
> “As compared with the baseline reduction in proteinuria that was observed at the end of part A of the study, in the exploratory part B of the study (in which data from nine participants were assessed), the mean urinary protein-to-creatinine ratio increased from −47.6% to −30.1% at week 4.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.1.2.6.2-7"></a>

### Electrocardiographic effects in healthy adults

> “There was no evidence of effects of inaxaplin on ECG parameters.”
> “There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec.”
> “No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.6.2-8"></a>

### Serum creatinine, lipids, and leukocyte counts in healthy adults

> “Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
